signumia
Data is being collected. The dashboard will appear when it is available.
SYMBOL
Data is being collected. The dashboard will appear when it is available.
MRK

Close price

$120.60

Latest price

$123.70

Change vs close

+2.57%

Current price: $123.70

Market cap

305.52B

Pre-market and after-hours data may be partial or delayed depending on the source and licensing.

Merck & Company, Inc.

MRK

NYSE · Health Care · Biotechnology: Pharmaceutical Preparations

Company Profile

Merck Animal Health, a division of Merck & Co., Inc., Rahway, N. J., USA, is a global animal health business committed to The Science of Healthier Animals. For more than 130 years, we have pioneered groundbreaking science. Today, we are driven by continuous innovation to develop breakthrough medicines, vaccines and technology. Rooted in direct experience on the farm and in the clinic, we work hand in hand with our customers every step of the way. Our singular focus is to empower those who care for animals, helping them manage their vital responsibility with confidence. Because when it comes to animal health, no one sees it like we do.

Website

https://www.merck.com

Country

NJ

Sector

Health Care

Industry

Biotechnology: Pharmaceutical Preparations

CIK

0000310158

Candlestick Chart

1D · Data source: loading

Loading candle data

Quarterly Performance Snapshot

Actual revenue and net income based on quarterly filings

Q2 Aug 2026

Quarterly Snapshot

Q2 Aug 2026

Mix

327.3B

Market cap

93.35%

305.52B

Expected quarterly revenue

5.05%

16.52B

Estimated quarterly net income

1.61%

5.25B

Market cap / expected revenue

18.49x

Revenue

Forecast

16.52B

Previous quarter

+1.46%

Net income

Forecast

5.25B

Previous quarter

+223.92%

Revenue and Net Income Trend

RevenueNet income

Quarterly Performance

13 quarters

Financial Statements

SEC Filings

12 filings shown

Open the original SEC filings to view the full document.

FormFiling DateReport DateAccessionLink
11-KJun 24, 2026Dec 31, 20250000310158-26-000196Document
11-KJun 24, 2026Dec 31, 20250000310158-26-000194Document
11-KJun 24, 2026Dec 31, 20250000310158-26-000192Document
4Jun 2, 2026May 29, 20260000310158-26-000177Document
4Jun 2, 2026May 29, 20260000310158-26-000171Document
4Jun 2, 2026May 29, 20260000310158-26-000166Document
4Jun 2, 2026May 29, 20260000310158-26-000163Document
4Jun 2, 2026May 29, 20260000310158-26-000161Document
4Jun 2, 2026May 29, 20260000310158-26-000159Document
4Jun 2, 2026May 29, 20260000310158-26-000157Document
4Jun 2, 2026May 29, 20260000310158-26-000155Document
4Jun 2, 2026May 29, 20260000310158-26-000153Document

Latest News

12 articles
ZacksJun 25, 2026, 12:00 AMnasdaq

Gilead's Breast Cancer Drug Trodelvy Wins FDA Nod for Expanded Use

GILD wins FDA approval to expand Trodelvy into first-line metastatic triple-negative breast cancer, opening a broader treatment opportunity.

Open article
ZacksJun 25, 2026, 12:00 AMnasdaq

MRK Gets EU Nod for Keytruda & Padcev Combination in Bladder Cancer

Merck wins EU approval for Keytruda plus Padcev in patients with resectable muscle-invasive bladder cancer who are ineligible for cisplatin-based chemotherapy.

Open article
RTTNewsJun 25, 2026, 12:00 AMnasdaq

EC Approves Merck's KEYTRUDA And KEYTRUDA SC In Treating Muscle-Invasive Bladder Cancer In The EU

(RTTNews) - Merck & Co. Inc. (MRK), a healthcare company, on Wednesday reported the receipt of approval from the European Commission for KEYTRUDA in combination with Padcev as a neoadjuvant treatment of muscle-invasive bladder cancer. The approval also extends to KEYTRUDA SC in a

Open article
ZacksJun 24, 2026, 12:00 AMnasdaq

Gilead Wins EC Approval to Expand Trodelvy's Label in Metastatic TNBC

Gilead secures EC approval to expand Trodelvy into first-line metastatic TNBC, marking a new treatment option and broadening its oncology reach.

Open article
ZacksJun 23, 2026, 12:00 AMnasdaq

EXEL Down on Colorectal Cancer Study Data on Zanzalintinib

Exelixis falls after STELLAR-303 misses statistical significance in overall survival for a key colorectal cancer subgroup, raising approval uncertainty.

Open article
ZacksJun 23, 2026, 12:00 AMnasdaq

Merck's Anti-TL1A Antibody Meets Goal in Ulcerative Colitis Study

MRK's tulisokibart meets goals in a late-stage ulcerative colitis study, strengthening a key pipeline asset as the company looks beyond Keytruda.

Open article
BNK InvestJun 23, 2026, 12:00 AMnasdaq

FDL, MRK, PEP, BMY: Large Inflows Detected at ETF

Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the First Trust Morningstar Dividend Leaders Index Fund (Symbol: FDL) where we have detected an approximate $1.9 billion dollar inflow -- that's a 26.8%

Open article
ZacksJun 23, 2026, 12:00 AMnasdaq

Pfizer's Mixed Phase III Data for Sigvotatug Vedotin in NSCLC

PFE's phase III NSCLC study misses a key survival goal overall, but a large subgroup shows favorable survival trends vs docetaxel.

Open article
ZacksJun 22, 2026, 12:00 AMnasdaq

AbbVie and Merck Face-Off: Which Pharma Stock Has the Lead?

ABBV's successful transition beyond Humira and growth from newer medicines give it an edge over MRK in this oncology-immunology showdown.

Open article
ZacksJun 18, 2026, 12:00 AMnasdaq

Biogen to Strengthen Immunology Pipeline With $1B RayThera Buyout

BIIB is set to acquire RayThera for up to $1 billion, adding anti-inflammatory candidates that could expand its immunology pipeline and future growth.

Open article
ZacksJun 18, 2026, 12:00 AMnasdaq

GSK's Utebzi Wins FDA Nod for Complicated Urinary Tract Infections

GSK wins FDA approval for Utebzi, the first oral carbapenem for complicated UTIs, further expanding its anti-infectives portfolio.

Open article
ZacksJun 17, 2026, 12:00 AMnasdaq

The Zacks Analyst Blog Highlights Gilead Sciences, Merck and GSK

Gilead Sciences won FDA acceptance for a filing that could expand Yeztugo into a once-weekly oral HIV prevention option, broadening its HIV portfolio.

Open article